适体技术市场份额| 2031 年全球增长和规模

Publication Month : Feb 2024

  • Report Code : TIPRE00037801
  • Category : Healthcare IT
  • Status : Upcoming
  • No. of Pages : 150
Inquire Before Buy

PRICING

$5190

$4671

[研究报告]适配体技术市场规模预计将从2022年的21.688亿美元增长到2030年的98.038亿美元;预计 2022 年至 2030 年市场复合年增长率将达到 20.8%。

市场洞察和分析师观点:

在多轮不规则分区和 PCR 扩增中,从任意寡核苷酸序列文库中优选获得适体。适体选择通常需要十多个序列。构建适体的主要技术有两种:配体系统进化(SELEX)方法和非SELEX技术。 SELEX方法有六个主要步骤:生成单链寡核苷酸文库、用靶标靶向随机寡核苷酸孵育文库、结合序列洗脱和扩增、PCR扩增后获得单链DNA、反选或负选择以及跟踪选择进展。对产生的序列进行分析,发现百分比最高的分类序列是潜在的适体。基因组 SELEX、spiegelmer、photo SELEX、in silico-SELEX、in vivo SELEX、monoLEX 和 Whole cell-SELEX 是 SELEX 方法的变体。

 适配体技术市场包括技术、类型、应用、最终用户和地理位置。根据北美、欧洲、亚太地区 (APAC)、中东和美国等主要国家对适配体技术的市场进行了分析。非洲 (MEA) 和南美洲中美洲 (SCAM)。

关键驱动因素,例如新兴市场中慢性病医疗保健设施的不断增长以及医疗保健提供者为开发基于适体的疗法而进行的临床试验的增加适体的帮助正在帮助市场增长。此外,用于适配体研究的风险投资资金不断增加以及与制药公司和研究机构的合作也为适配体技术市场的增长提供了机会。例如,2021 年,Optimer 试剂和治疗药物开发商 Aptamer Group 宣布与全球生物制药公司阿斯利康 (AstraZeneca) 延长当前协议。该协议评估了使用基于 Optimer 的策略靶向肾细胞的潜力,并探讨了开发下一代药物递送载体 Optimer-药物缀合物的可能性。此次协议延期将进一步发挥 Aptamer Group 在开发基于 aptamer 的技术方面的专业知识和知识,以及阿斯利康在开发心血管、肾脏和代谢 (CVRM) 疗法方面的领导地位。

战略洞察

增长动力:

相对于单克隆抗体的优势推动适配体市场增长

与适配体相比,单克隆抗体具有一定的优势限制。适体在靶向小分子(30 至 60 nt)方面表现更好。此外,单克隆抗体对温度敏感,适配体在室温下稳定,保质期较长。变性是可逆的。此外,抗体是通过在动物原型或重组 DNA 技术中建立免疫反应来开发的。

另一方面,可以使用较便宜的化学方法合成适体。因此,适配体对于开发新的治疗药物和诊断试剂盒更具吸引力。此外,适体的体外选择方法可能包括正选择和负选择步骤,从而确保高特异性。只需要几个纳摩尔就可以进行选择,并且筛选出很大的分子多样性。大的抗体尺寸限制了膜的通透性,从而在靶向致密组织时造成困难。独特的双特异性抗体已被说服能够穿过血脑屏障,但传统抗体不能。已从美洲驼、鲨鱼和骆驼中分离出小抗体(~90 kDa)。这些小抗体的片段被称为纳米抗体 (~ 15 kDa),显示出作为亲和剂的前景,但尚未广泛使用。

适配体已揭示了体外和体外增强的组织访问能力。体内成像。一些适体复合物和适体已被证明可以穿过血脑屏障,甚至进入细胞。碱基对选择了能够进入特定类型细胞的适体。单克隆抗体的生产是一个耗时且复杂的生物过程。分批补料和灌注培养工艺已被创建以提高产量并加速生物生产过程。尽管如此,培养物污染仍然是一个问题,因为适体是化学合成的,整批材料可能会受到损害。因此,不存在生物污染的风险,并且批次间的一致性良好。此外,需要有关适体序列和任何修饰的信息,以继续长期获取以前生产和验证的适体。正如最近许多影响适体的体内研究所证明的那样,小 DNA 和 RNA 适体基本上是非免疫原性的。因此,它们无需大量修饰即可在体内使用。

“适配体技术市场”正在蓬勃发展。根据技术、类型、应用程序和最终用户进行细分。适配体技术市场按技术分为SELEX技术、MARAS技术和其他技术。 SELEX 技术细分市场将在 2022 年占据市场主导地位,预计该细分市场将在预测期内实现最高增长。全球适体技术市场的类型部分由核酸适体和肽适体组成。核酸片段进一步细分为基于DNA的适体、基于RNA的适体和基于XNA的适体。核酸细分市场在 2022 年获得了最高的市场价值。此外,预计从 2022 年到 2030 年,核酸细分市场将以最高的复合年增长率增长。

适配体技术市场(按应用) ,分为诊断、治疗、研究和开发。诊断市场将在 2022 年占据主导地位。按最终用户划分,市场分为生物技术和制药公司、学术和研究机构以及合同研究组织。到 2022 年,生物技术和制药公司预计将占据重要的市场份额,并预计在预测期内保持其地位。

细分分析:

全球适配体技术市场类型细分为核酸和肽适体。核酸片段进一步细分为基于DNA的适体、基于RNA的适体和基于XNA的适体。核酸细分市场在 2022 年获得了最高的市场价值。DNA 适体本质上更稳定,制造成本更低。 RNA适体通常具有更多样化的三维构象和更强的链内RNA-RNA相互作用,这可能会增加结合亲和力和特异性。一种DNA适体(AS1411)和一种L型RNA适体(NOX-A12)已接受治疗癌症的临床试验。 AS1411原名ARGO100(Antisoma),是一种26-nt G-四链体DNA寡核苷酸(不是由经典SELEX204进化而来),是第一个进入人类癌症治疗临床试验的适配体。

最终用户的适体技术市场 - 2022年和2030年

按最终用户划分,市场分为生物技术和制药公司、学术界以及研究机构和合同研究组织。到 2022 年,生物技术和制药公司预计将占据重要的市场份额,并预计在预测期内保持其地位。由于该行业的进步,推动该细分市场增长的因素。 2019 年 2 月,Base Pair Biotechnologies, Inc., The Aptamer Discovery Company™ 宣布获得 SBIR 拨款,用于开发基于适体的阿片类药物 POC 测试,以快速诊断新生儿戒断综合症。这笔资金将用于开发一个新平台,用于检测新生儿中的阿片类药物及其主要代谢物,从而实现快速治疗。

此外,2020年10月,该公司还宣布该公司已被选为 XPRIZE 快速 Covid 测试竞赛的半决赛选手。 Base Pair 将在新型电化学传感器中使用其专有的适体来快速测试唾液样本。作为竞赛的一部分,他们将采集灭活病毒抗原样本并以盲法进行测试。

区域分析 - 适体技术市场:

根据地理位置,全球适配体技术市场分为五个区域:北美(美国、加拿大和墨西哥)、欧洲(英国、德国、法国、意大利、西班牙和欧洲其他地区)、亚太地区 (APAC)(澳大利亚、中国、印度、韩国、日本和亚太地区其他地区)、南美和北美地区。中美洲 (SCAM)(巴西、阿根廷、南美洲和中美洲其他地区)以及中东和非洲非洲 (MEA)(沙特阿拉伯、南非、阿联酋、中东和非洲其他地区)。

2022 年,北美占据全球最重要的适配体技术市场分享。预计亚太地区的增长速度将更快,从 2022 年至 2030 年起复合年增长率最高。

北美在手术机器人市场中占有最大份额。该地区的市场分为美国、加拿大和墨西哥。由于美国的不断发展和进步以及 FDA 批准的增加,该地区的市场增长正在增长。美国是北美乃至全球适体技术市场最重要的贡献者。

根据美国疾病控制与预防中心 (CDC) 的数据,在 40 岁至 85 岁的人群中,年龄相关性黄斑变性 (AMD) 的发病率从 2% 增加到 46.6%。分别。此外,按州划分,AMD 的常见患病率从低到高不等。例如,哥伦比亚特区最低为 6.2%,佛罗里达州最高为 18.3%。这种疾病通常与视网膜色素上皮周围未降解的废物聚集有关,这些废物是由于眼睛的修复和再生过程而形成的。 AMD 有两种形式,即湿性 AMD 和干性 AMD,先于中心性视力丧失。适体作为治疗大多数眼睛相关疾病的灵丹妙药的能力是巨大的。美国Creative Biolabs公司已经确定了最佳的适配体开发平台,并在适配体应用研究方面拥有丰富的经验。此外,公司还可以为全球客户提供全面的适体开发服务,以促进项目成功。

全球范围内已开发出多种基于核酸的针对黄斑变性的疗法。例如,2023 年 9 月,FDA 批准了 Iveric Bio/Astellas 的 avacincaptad pegol (Izervay),用于治疗继发于年龄相关性黄斑变性的地理萎缩 (GA)。该药物是第二个获得 FDA 批准的 RNA 适体,也是第二个用于治疗这种失明的补体靶向药物。

行业发展和未来机遇 -适配体技术市场:

适配体技术市场领先企业采取的各种举措如下:

  1. 2023 年 6 月,Aptamer Group 与 Neuro-Bio 合作开发阿尔茨海默病诊断测试。新型 Optimer 结合剂开发商 Aptamer Group 和牛津生物技术公司 Neuro-Bio 于 2023 年 6 月 14 日宣布开发 Optimer 结合剂,可进行侧向层析测试以早期诊断阿尔茨海默病。 Neuro-Bio 的公司已为这些粘合剂申请了专利,因为它们具有与目标生物标志物特异性结合的性能以及鼻粘膜基质中的功能。
  2. 2021 年 3 月,Optimer 试剂和治疗药物开发商 Aptamer Group,宣布与全球生物制药公司阿斯利康 (AstraZeneca) 续约。该协议评估了使用基于 Optimer 的策略靶向肾细胞的潜力,并探讨了下一代药物递送载体 Optimer-药物缀合物的可行性。此次协议延期将进一步发挥 Aptamer Group 在开发基于 aptamer 的技术方面的专业知识和知识,以及阿斯利康在开发心血管、肾脏和代谢 (CVRM) 疗法方面的领导地位。
  3. 2023 年 10 月知识产权技术开发和商业化公司 Zentek Ltd. 宣布成立一家全资子公司,该子公司将拥有与麦克马斯特大学合作的所有基于适配体的技术的独家全球许可权。该许可协议包括快速检测平台和李英福博士及其团队最近开发的基于适配体的平台技术,该技术通过 Matthew Miller 博士及其团队进行的临床前研究显示出作为治疗药物的前景。
  4. 2023 年 3 月,致力于推动生命科学行业创新的新型 Optimer 结合剂开发商 Aptamer Group plc 宣布推出其新试剂 Optimer-Fc,用于自动化免疫组织化学 (IHC) 工作流程。该公司正在与 IHC 市场三大公司之一合作,验证 Optimer-Fc 在其自动化 IHC 平台中的性能。目前正在与寻求试验 Optimer-Fc 的两家排名前 10 的制药公司进行谈判。

竞争格局和主要公司 - 适体技术市场:

SomaLogic;适体组;阿普塔德尔疗法;碱基对生物技术;诺克森制药公司;维沃尼克斯公司; Aptagen 有限责任公司;三联生物技术公司;阿尔特穆恩有限责任公司; AM生物技术;市场公司。这些公司专注于新技术、现有产品的进步和地域扩张,以满足全球不断增长的消费者需求。

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

  • SomaLogic
  • Aptamer Group
  • Aptadel Therapeutics
  • Base Pair Biotechnologies
  • Noxxon Pharma
  • Vivonics Inc.
  • Aptagen, LLC
  • TriLink Biotechnologies
  • Altermune LLC
  • AM Biotechnologies

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports